M&A - ANI PHARMACEUTICALS INC

Form Type: DEF 14A

Filing Date: 2025-04-10

Corporate Action: Acquisition

Type: New

Accession Number: 000102302425000035

Filing Summary: ANI Pharmaceuticals, Inc. experienced strong financial results in 2024, with total revenue reaching $614.4 million, a 26% increase from 2023. The company reported record adjusted non-GAAP EBITDA of $156.0 million, a 17% year-over-year increase, and an adjusted non-GAAP earnings per share of $5.20, up 10% from the previous year. A significant corporate development was the acquisition of Alimera Sciences in September, which enhanced ANI's rare disease portfolio. The lead product, Cortrophin Gel, achieved net sales of $198.1 million, showing year-over-year growth of 77%. The company aims to leverage expanded commercialization efforts to increase prescribing for Cortrophin Gel and anticipates further growth driven by this product and others acquired. The Proxy Statement provides insights into the upcoming Annual Meeting, scheduled for May 22, 2025, where stockholders will vote on key proposals, including the election of directors, the appointment of independent auditors, and changes to stock incentive plans. The Board of Directors unanimously recommends that stockholders vote in favor of all proposals.

Document Link: View Document